Alamar Biosciences, Inc. Common Stock (ALMR)

About Alamar Biosciences, Inc. Common Stock

Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 82 institutions reported holding ALMR, with 24.4 million shares worth $660.4 million in aggregate. The largest reported holder was Sands Capital Ventures, with 4.2 million shares worth $114.6 million. Of the 5 largest holders listed below, all 5 opened new positions in ALMR during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions